



Our mission is to deliver a cure without compromise for patients through allogeneic high-precision cell therapy

About Orca Bio

Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. Our manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products that have the potential to transform allogeneic cell therapy.

Redefining Cell Therapy Through the Power of Precision

While many patients receiving a conventional allogeneic or autologous graft (allograft) experience treatment success, data show its curative potential may be undermined by relapse, infection and graft versus host disease (GvHD). Our high-precision approach is designed to offer the hope of a cure while reducing the risk of toxicities and treatment-related mortality.

Orca Bio’s investigational high-precision cell therapies use a mix of natural immune cells and stem cells to replace a patient’s diseased blood and immune system with a healthy one. Orca-T is Orca Bio’s lead investigational allogeneic T-cell immunotherapy designed to treat hematological malignancies like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL).

Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a pivotal, randomized Phase 3 clinical study called Precision-T.

Manufacturing Excellence

Orca Bio has built its own centralized manufacturing platform to ensure consistent and reliable delivery of our high-precision cell therapies at scale. Importantly, we have consistently achieved donor to patient vein-to-vein turnaround times of less than 72 hours across our ongoing clinical trials.

At Orca Bio, we believe this is only the beginning. We are advancing our next-generation programs to expand our pipeline to bring cell therapy to more patients who could benefit, including potential application in autoimmune disease.

Orca Bio Partners with Leading Treatment Centers

Working with leading institutions and top transplant centers, we have taken a rigorous approach to the design and implementation of our clinical trial programs.

- City of Hope
- Memorial Sloan Kettering Cancer Center
- University of Texas MD Anderson Cancer Center
- Weill Cornell Medicine – New York-Presbyterian Hospital
- Moffitt Cancer Center
- Stanford Health Care
- University of Chicago Medical Center
- Sarah Cannon Research Institute
- Ohio State University
- Ronald Reagan UCLA Medical Center

FAST FACTS

Year Founded
2016

Locations
**Menlo Park, CA
(Headquarters)**

**Sacramento, CA
(Commercial and Clinical
Manufacturing Facilities)**

Number of Employees
170+

Number of Patients
Treated in Clinical Trials
450+